Get started
Author

Yolanda Fernandez Diez

Observed name: Y. Fernandez Diez
ORCID: 0000-0002-1892-4071
Observed ORCID: 0000-0002-1892-4071
OpenAlex ID: A5063589741
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
2025 · Florence Joly, Alexandra Leary, et al. · Nature Communications · 14
PDF
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
2024 · Florence Joly, Fernando Bazan, et al. · JNCI Cancer Spectrum · 5
PDF
Multicentre randomized phase II trial of olaparib as maintenance therapy in platinum-sensitive advanced endometrial carcinoma: The GINECO-UTOLA study.
2020 · Florence Joly, Pierre Emmanuel Brachet, et al. · Journal of Clinical Oncology · 4
27O Long-term survival outcomes and immune subgroup analyses in the COLIBRI study: Induction nivolumab plus ipilimumab with immunotherapy maintenance (ICB) prior to and following chemoradiation (RT-CT) in locally advanced cervical cancer (LACC)
2026 · F. Joly Lobbedez, D. Bello Roufai, et al. · ESMO Open · 3
PDF
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al. · Clinical Cancer Research · 2
Characterization of Proficient Mismatch Repair Endometrial Cancer Subpopulation of the Randomized Phase Ii Gineco-utola Study
2026 · Francois Cherifi, Raphaël Leman, et al. · International Journal of Gynecological Cancer
Data from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al.
Supplementary Table S1 from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al.
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial
2025 · Guillaume Beinse, Karen Leroy, et al. · International Journal of Gynecological Cancer
1160P Immune landscape heterogeneity in endometrial carcinoma: Ancillary analyses of GINECO UTOLA trial and CARPEM cohort
2025 · J. Berthet, A. Kime, et al. · Annals of Oncology
1133P GREAT: Clinical outcomes from a prospective study of 1,456 patients (pts) with advanced ovarian cancer (AOC), including theranostic biomarker analysis (BRCA and genomic instability score) and paired tumor/DNA collection in the PARP inhibitor era
2025 · T. De La Motte Rouge, L. Deiana, et al. · Annals of Oncology
Characterization Of The PMMR Advanced Endometrial Cancer Subpopulation Of The Randomized Phase II GINECO-UTOLA Study
2025 · François Cherifi, Raphael Leman, et al. · International Journal of Gynecological Cancer
41MO ESR1 mutation in untreated endometrial cancer: Prevalence, characteristics and prognostic implications from the UTOLA trial
2024 · F. Blanc-Durand, S. Nikolaev, et al. · ESMO Open
PDF
Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study.
2023 · Florence Joly, Elsa Kalbacher, et al. · Journal of Clinical Oncology
Works count: 14
Citation count: 28
H-index: 3
I10-index: 1
Year
Topic
Type